Scilex Holding Company announced it has received approval of a New Drug Submission (NDS) from Health Canada's Pharmaceutical Drugs Directorate for ELYXYB®.
ELYXYB® is approved for the acute treatment of migraine with or without aura in adults in Canada. This approval expands the commercial reach of ELYXYB into a new national market.
Clinical studies demonstrated that patients treated with ELYXYB® experienced pain relief in as little as 15 minutes, with significant pain relief compared to placebo within 45 minutes in approximately 50% of patients. Canada is considered a strategic market for global pharmaceutical expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.